melphalan hydrochloride · Acrotech Biopharma · NDA 207155
Evomela
Earliest generic entry, as listed
30 Jan 2034
Blocked by patent: US 10040872.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10040872 | drug product · sets the listed date | 30 Jan 2034 |
| US 9493582 | drug product | 27 Feb 2033 |
| US 10940128 | drug product, use U-3086 | 14 Jun 2030 |
| US 10864183 | drug product | 28 May 2030 |
| US 11020363 | drug product | 28 May 2030 |
| US 8410077 | drug product | 13 Mar 2029 |
| US 9200088 | drug product | 13 Mar 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207155 · 001 · RLD | powder, intravenous | EQ 50MG BASE/VIAL | 30 Jan 2034 |